Praluent Safety Study Requirements: A Backdoor To Ensuring Outcomes Trial Completion?
Executive Summary
Agency requires three post-marketing studies under the FDA Amendments Act's drug safety authorities; Sanofi says some of the requirements will be answered by data collected in the ongoing ODYSSEY OUTCOMES trial.
You may also be interested in...
Gilead, US FDA Ponder Innovative Designs For Descovy HIV Prevention Study In Women
Advisory committee sent a clear message that pre-exposure prophylaxis studies are needed in cisgender women, but what those studies might look like, and whether the agency can exercise its statutory authorities to ensure they are conducted, is less clear.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.